Alanine News and Research

RSS
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

Combination treatment prevents disease progression in patients with advanced melanoma

Combination treatment prevents disease progression in patients with advanced melanoma

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

Abbvie announces multiple study results of veliparib investigational compound in NSCLC patients

UCLA research may lead to novel treatment for PH1

UCLA research may lead to novel treatment for PH1

Thyroxine may overcome mutated thyroid hormone receptor effects

Thyroxine may overcome mutated thyroid hormone receptor effects

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Novartis LDE225 Phase II study for advanced basal cell carcinoma meets primary endpoint

Women with elevated levels of liver enzyme prior to pregnancy twice as likely to develop gestational diabetes

Women with elevated levels of liver enzyme prior to pregnancy twice as likely to develop gestational diabetes

Obeticholic acid meets primary composite endpoint in Phase III study

Obeticholic acid meets primary composite endpoint in Phase III study

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Ceritinib ‘highly active’ in advanced ALK-rearranged NSCLC

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Novartis’ investigational compound achieves overall response rate of 58% in patients with ALK+ NSCLC

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Nintedanib plus docetaxel shows second-line efficacy in recurrent NSCLC

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Monitoring individuals with chronic HBV is cost-effective strategy for China

Monitoring individuals with chronic HBV is cost-effective strategy for China

Probe mimics pathogen's amino acids, solving mystery behind Chlamydiae cell wall

Probe mimics pathogen's amino acids, solving mystery behind Chlamydiae cell wall

FOXO3 transcription factor may protect against alcohol-induced liver injury

FOXO3 transcription factor may protect against alcohol-induced liver injury

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Testosterone treatment in hypogonadal men may reduce cardiovascular disease risk

Oil spill exposure appears to play role in development of hematologic and hepatic toxicity

Oil spill exposure appears to play role in development of hematologic and hepatic toxicity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.